Search Results - "Fleming, G. F."

UGT1A128 polymorphism as a determinant of irinotecan disposition and toxicity by LYER, L, DAS, S, JANISCH, L, WEN, M, RAMIREZ, J, KARRISON, T, FLEMING, G. F, VOKES, E. E, SCHILSKY, R. L, RATAIN, M. J

“…The metabolism of irinotecan (CPT-11) involves sequential activation to SN-38 and detoxification to the pharmacologically inactive SN-38 glucuronide (SN-38G)…”
Get full text

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study by Fleming, G. F., Filiaci, V. L., Bentley, R. C., Herzog, T., Sorosky, J., Vaccarello, L., Gallion, H.

“…Background: This study was performed to determine whether 24-h paclitaxel plus doxorubicin and filgrastim was superior to cisplatin plus doxorubicin in…”
Get full text

Sorafenib Dose Escalation Is Not Uniformly Associated With Blood Pressure Elevations in Normotensive Patients With Advanced Malignancies by Karovic, S, Wen, Y, Karrison, T G, Bakris, G L, Levine, M R, House, L K, Wu, K, Thomeas, V, Rudek, M A, Wright, J J, Cohen, E E W, Fleming, G F, Ratain, M J, Maitland, M L

“…Hypertension after treatment with vascular endothelial growth factor (VEGF) receptor inhibitors is associated with superior treatment outcomes for advanced…”
Get full text

A phase II study single agent of aflibercept (VEGF Trap) in patients with recurrent or metastatic gynecologic carcinosarcomas and uterine leiomyosarcoma. A trial of the Princess Margaret Hospital, Chicago and California Cancer Phase II Consortia by Mackay, H.J, Buckanovich, R.J, Hirte, H, Correa, R, Hoskins, P, Biagi, J, Martin, L.P, Fleming, G.F, Morgan, R, Wang, L, Polintan, R, Oza, A.M

“…Abstract Objective The aim of this multi-institutional non randomized phase II trial was to determine the efficacy and safety of single agent aflibercept (VEGF…”
Get full text

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? by Regan, M.M., Pagani, O., Walley, B., Torrisi, R., Perez, E.A., Francis, P., Fleming, G.F., Price, K.N., Thürlimann, B., Maibach, R., Castiglione-Gertsch, M., Coates, A.S., Goldhirsch, A., Gelber, R.D.

“…The role of chemotherapy in addition to combined endocrine therapy for premenopausal women with endocrine-responsive early breast cancer remains an open…”
Get full text

Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology by RECHT, Abram, EDGE, Stephen B, KRAUSE, David A, KUSKE, Robert R, LANGER, Amy S, SLEDGE, George W, WHELAN, Timothy J, PFISTER, David G, SOLIN, Lawrence J, ROBINSON, David S, ESTABROOK, Alison, FINE, Richard E, FLEMING, Gini F, FORMENTI, Silvia, HUDIS, Clifford, KIRSHNER, Jeffrey J

“…To determine indications for the use of postmastectomy radiotherapy (PMRT) for patients with invasive breast cancer with involved axillary lymph nodes or…”
Get full text

A phase I study of sirolimus and bevacizumab in patients with advanced malignancies by Cohen, E.E.W, Sharma, M.R, Janisch, L, Llobrera, M, House, L, Wu, K, Ramirez, J, Fleming, G.F, Stadler, W.M, Ratain, M.J

“…Abstract Background We performed a single institution, phase I study of sirolimus and bevacizumab, in order to determine the dose limiting toxicity (DLT) and…”
Get full text

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer by Liu, J.F., Barry, W.T., Birrer, M., Lee, J.-M., Buckanovich, R.J., Fleming, G.F., Rimel, B.J., Buss, M.K., Nattam, S.R., Hurteau, J., Luo, W., Curtis, J., Whalen, C., Kohn, E.C., Ivy, S.P., Matulonis, U.A.

“…Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase II study, combination…”
Get full text

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study by Fleming, G.F., Pagani, O., Regan, M.M., Walley, B.A., Francis, P.A.

Get full text

impact of sharing results of a randomized breast cancer clinical trial with study participants by Partridge, Ann H, Wolff, A. C, Marcom, P. K, Kaufman, P. A, Zhang, L, Gelman, R, Moore, C, Lake, D, Fleming, G. F, Rugo, H. S, Atkins, J, Sampson, E, Collyar, D, Winer, E. P

“…Background There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the…”
Get full text

Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT by Regan, M.M., Walley, B.A., Francis, P.A., Fleming, G.F., Láng, I., Gómez, H.L., Colleoni, M., Tondini, C., Pinotti, G., Salim, M., Spazzapan, S., Parmar, V., Ruhstaller, T., Abdi, E.A., Gelber, R.D., Coates, A.S., Goldhirsch, A., Pagani, O.

“…Recent breast cancer treatment guidelines recommend that higher-risk premenopausal patients should receive ovarian function suppression (OFS) as part of…”
Get full text

Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer by BAIDAS, S. M, WINER, E. P, FLOCKHART, D, JOHNSON, M. D, HAWKINS, M. J, LIPPMAN, M. E, HAYES, D. F, FLEMING, G. F, HARRIS, L, PLUDA, J. M, CRAWFORD, J. G, YAMAUCHI, H, ISAACS, C, HANFELT, J, TEFFT, M

“…To determine the efficacy, safety, pharmacokinetics, and effect on serum angiogenic growth factors of two dose levels of thalidomide in patients with…”
Get full text

Genomic characterisation of hormone receptor-positive breast cancer arising in very young women by Luen, S.J., Viale, G., Nik-Zainal, S., Savas, P., Kammler, R., Dell’Orto, P., Biasi, O., Degasperi, A., Brown, L.C., Láng, I., MacGrogan, G., Tondini, C., Bellet, M., Villa, F., Bernardo, A., Ciruelos, E., Karlsson, P., Neven, P., Climent, M., Müller, B., Jochum, W., Bonnefoi, H., Martino, S., Davidson, N.E., Geyer, C., Chia, S.K., Ingle, J.N., Coleman, R., Solbach, C., Thürlimann, B., Colleoni, M., Coates, A.S., Goldhirsch, A., Fleming, G.F., Francis, P.A., Speed, T.P., Regan, M.M., Loi, S.

“…Very young premenopausal women diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+HER2−) early breast cancer (EBC)…”
Get full text

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia by Hirte, H, Lheureux, S, Fleming, G.F, Sugimoto, A, Morgan, R, Biagi, J, Wang, L, McGill, S, Ivy, S.P, Oza, A.M

“…Abstract Purpose Cediranib is a potent multitargeted inhibitor of vascular endothelial growth factor receptor (VEGFR) 1, 2 and 3. The study was initiated to…”
Get full text

Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction by Fleming, G. F., Schilsky, R. L., Schumm, L. P., Meyerson, A., Hong, A. M., Vogelzang, N. J., Ratain, M. J.

“…Background: Patients with hepatic or renal dysfunction are often treated with 5-fluorouracil (5-FU), but there are few data to confirm the safety of this…”
Get full text

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group study by Grushko, T.A, Filiaci, V.L, Mundt, A.J, Ridderstråle, K, Olopade, O.I, Fleming, G.F

“…Abstract Objectives. To investigate the frequency and potential prognostic or predictive value of HER-2 amplification or overexpression in advanced and…”
Get full text

Invariant p53 immunostaining in primary and recurrent breast cancer by Poelman, S.M., Heimann, R., Fleming, G.F., Recant, W.M., Conzen, S.D.

“…In animal models, acquired mutations of the p53 gene that result in increased p53 protein expression are associated with tumour recurrence following…”
Get full text

Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors by Eng, C., Mauer, A. M., Fleming, G. F., Bertucci, D., Rotmensch, J., Jacobs, R. H., Ratain, M.J.

“…Summary Background: The combination of doxorubicin, paclitaxel, and cisplatin has activity in gynecologic malignancies but requires colony stimulating factor…”
Get full text

QUADRA: A phase II, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) in 4th or later line of therapy: Results from the tBRCAmut subset by Moore, K.N., Secord, A.A., Geller, M., Miller, D.S., Cloven, N.G., Fleming, G.F., Wahner Hendrickson, A.E., Azodi, M., DiSilvestro, P., Oza, A., Cristea, M., Berek, J.S., Chan, J.K., Rimel, B.J., Li, Y., Luptakova, K., Clark, R., Matulonis, U.A., Monk, B.J.

Get full text

Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study by O'Reilly, S, Fleming, G F, Barker, S D, Walczak, J R, Bookman, M A, McGuire, 3rd, W P, Schilder, R J, Alvarez, R D, Armstrong, D K, Horowitz, I R, Ozols, R F, Rowinsky, E K

“…A phase I and pharmacologic study to evaluate the feasibility of administering paclitaxel (PTX) in combination with topotecan (TPT) without and with…”
Get more information